Annual FCF
-$171.05 M
-$119.49 M-231.75%
31 December 2023
Summary:
Mersana Therapeutics annual free cash flow is currently -$171.05 million, with the most recent change of -$119.49 million (-231.75%) on 31 December 2023. During the last 3 years, it has fallen by -$95.88 million (-127.55%). MRSN annual FCF is now -660.75% below its all-time high of $30.50 million, reached on 31 December 2016.MRSN Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$8.58 M
+$13.28 M+60.75%
30 September 2024
Summary:
Mersana Therapeutics quarterly free cash flow is currently -$8.58 million, with the most recent change of +$13.28 million (+60.75%) on 30 September 2024. Over the past year, it has increased by +$37.98 million (+81.58%). MRSN quarterly FCF is now -115.83% below its all-time high of $54.17 million, reached on 30 September 2022.MRSN Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$95.57 M
+$37.98 M+28.44%
30 September 2024
Summary:
Mersana Therapeutics TTM free cash flow is currently -$95.57 million, with the most recent change of +$37.98 million (+28.44%) on 30 September 2024. Over the past year, it has increased by +$95.15 million (+49.89%). MRSN TTM FCF is now -401.71% below its all-time high of $31.68 million, reached on 31 March 2016.MRSN TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MRSN Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -231.8% | +81.6% | +49.9% |
| 3 y3 years | -127.5% | +76.3% | +17.3% |
| 5 y5 years | -202.3% | +47.4% | -32.8% |
MRSN Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -231.8% | at low | -115.8% | +86.2% | -127.0% | +49.9% |
| 5 y | 5 years | -231.8% | at low | -115.8% | +86.2% | -127.0% | +49.9% |
| alltime | all time | -660.8% | at low | -115.8% | +86.2% | -401.7% | +49.9% |
Mersana Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$8.58 M(-60.8%) | -$95.57 M(-28.4%) |
| June 2024 | - | -$21.86 M(-33.3%) | -$133.54 M(-23.2%) |
| Mar 2024 | - | -$32.79 M(+1.4%) | -$173.92 M(+1.7%) |
| Dec 2023 | -$171.05 M(+231.7%) | -$32.35 M(-30.5%) | -$171.05 M(-10.3%) |
| Sept 2023 | - | -$46.55 M(-25.2%) | -$190.72 M(+111.9%) |
| June 2023 | - | -$62.23 M(+108.0%) | -$89.99 M(+23.0%) |
| Mar 2023 | - | -$29.92 M(-42.5%) | -$73.19 M(+42.0%) |
| Dec 2022 | -$51.56 M(-63.3%) | -$52.01 M(-196.0%) | -$51.56 M(+22.5%) |
| Sept 2022 | - | $54.17 M(-219.2%) | -$42.10 M(-68.2%) |
| June 2022 | - | -$45.43 M(+448.4%) | -$132.42 M(+8.7%) |
| Mar 2022 | - | -$8.28 M(-80.5%) | -$121.78 M(-13.4%) |
| Dec 2021 | -$140.64 M(+87.1%) | -$42.55 M(+17.7%) | -$140.64 M(+21.7%) |
| Sept 2021 | - | -$36.14 M(+3.9%) | -$115.59 M(+15.8%) |
| June 2021 | - | -$34.80 M(+28.2%) | -$99.83 M(+23.3%) |
| Mar 2021 | - | -$27.14 M(+55.0%) | -$80.99 M(+7.7%) |
| Dec 2020 | -$75.17 M | -$17.51 M(-14.1%) | -$75.17 M(+7.0%) |
| Sept 2020 | - | -$20.39 M(+27.8%) | -$70.24 M(+6.2%) |
| June 2020 | - | -$15.96 M(-25.1%) | -$66.16 M(+2.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | -$21.31 M(+69.5%) | -$64.60 M(-5.5%) |
| Dec 2019 | -$68.35 M(+20.8%) | -$12.58 M(-22.9%) | -$68.35 M(-5.0%) |
| Sept 2019 | - | -$16.31 M(+13.2%) | -$71.95 M(+8.4%) |
| June 2019 | - | -$14.40 M(-42.5%) | -$66.39 M(+3.8%) |
| Mar 2019 | - | -$25.06 M(+54.9%) | -$63.99 M(+13.1%) |
| Dec 2018 | -$56.59 M(+29.1%) | -$16.18 M(+50.6%) | -$56.59 M(+8.6%) |
| Sept 2018 | - | -$10.75 M(-10.4%) | -$52.11 M(-0.8%) |
| June 2018 | - | -$12.00 M(-32.0%) | -$52.55 M(+4.9%) |
| Mar 2018 | - | -$17.66 M(+50.8%) | -$50.10 M(+14.3%) |
| Dec 2017 | -$43.82 M(-243.7%) | -$11.71 M(+4.6%) | -$43.82 M(+134.5%) |
| Sept 2017 | - | -$11.19 M(+17.2%) | -$18.69 M(+51.5%) |
| June 2017 | - | -$9.55 M(-16.1%) | -$12.33 M(-1.8%) |
| Mar 2017 | - | -$11.38 M(-184.7%) | -$12.55 M(-141.2%) |
| Dec 2016 | $30.50 M(-397.5%) | $13.43 M(-377.7%) | $30.50 M(+78.7%) |
| Sept 2016 | - | -$4.84 M(-50.5%) | $17.07 M(-22.1%) |
| June 2016 | - | -$9.77 M(-130.8%) | $21.91 M(-30.8%) |
| Mar 2016 | - | $31.68 M | $31.68 M |
| Dec 2015 | -$10.26 M | - | - |
FAQ
- What is Mersana Therapeutics annual free cash flow?
- What is the all time high annual FCF for Mersana Therapeutics?
- What is Mersana Therapeutics annual FCF year-on-year change?
- What is Mersana Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Mersana Therapeutics?
- What is Mersana Therapeutics quarterly FCF year-on-year change?
- What is Mersana Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Mersana Therapeutics?
- What is Mersana Therapeutics TTM FCF year-on-year change?
What is Mersana Therapeutics annual free cash flow?
The current annual FCF of MRSN is -$171.05 M
What is the all time high annual FCF for Mersana Therapeutics?
Mersana Therapeutics all-time high annual free cash flow is $30.50 M
What is Mersana Therapeutics annual FCF year-on-year change?
Over the past year, MRSN annual free cash flow has changed by -$119.49 M (-231.75%)
What is Mersana Therapeutics quarterly free cash flow?
The current quarterly FCF of MRSN is -$8.58 M
What is the all time high quarterly FCF for Mersana Therapeutics?
Mersana Therapeutics all-time high quarterly free cash flow is $54.17 M
What is Mersana Therapeutics quarterly FCF year-on-year change?
Over the past year, MRSN quarterly free cash flow has changed by +$37.98 M (+81.58%)
What is Mersana Therapeutics TTM free cash flow?
The current TTM FCF of MRSN is -$95.57 M
What is the all time high TTM FCF for Mersana Therapeutics?
Mersana Therapeutics all-time high TTM free cash flow is $31.68 M
What is Mersana Therapeutics TTM FCF year-on-year change?
Over the past year, MRSN TTM free cash flow has changed by +$95.15 M (+49.89%)